A Decade-Late Diagnosis Sparked a New Model for Funding Precision Health

Nine years. That's how long doctors reassured Ariel Ganz that the lump in her breast was probably nothing, likely hormonal, nothing to worry about. It took an elective whole-body MRI, a scan she sought out on her own, to finally catch her breast cancer early enough to survive it.

That decade of being told she was probably fine, when she wasn't, left a mark. It also left her with a question that a lot of patients ask themselves after a close call: what if medicine had been built around people like me, instead of people like most?

Ganz had the training to actually chase that question. She holds a molecular nutrition PhD from Cornell and completed a genetics postdoc at Stanford. Three years ago, she turned that frustration and expertise into Arben Ventures, a fund built specifically around precision health and longevity. The founding thesis is straightforward: healthcare designed for population averages will keep missing the people who don't fit the average, and somebody needs to fund the alternative.

Think of it this way. A mammogram works reasonably well for a lot of women, but it struggles to read dense breast tissue, the kind that hides tumors instead of revealing them. A one-size-fits-all screening tool is a bit like a shoe store that only stocks size eight. Most customers walk out satisfied. The rest go home in pain, or in Ganz's case, undiagnosed for years.

Betting Early on Underrepresented Ideas

Arben has backed 83 early-stage digital health startups since its founding, spanning early cancer detection, AI-native health records, at-home care and personalized medicine. That's a broad net, but a deliberate one. Those 83 bets have since pulled in more than $200 million in follow-on funding from other investors, and four portfolio companies have already earned FDA clearances.

Ganz credits part of that record to timing. Arben often writes the first check into a company, sometimes before larger, more risk-averse funds are willing to commit at all.

"Even with a small check size, we're often the first investor outright, or the first in that round," Ganz said.

In some cases, she noted, Arben has effectively set the terms for a funding round while a much bigger investor waited on the sidelines to see how things played out. That willingness to move first isn't just a financial strategy. It shapes who gets funded in the first place. Ganz said 76% of Arben's capital has gone to underrepresented founders, and 34% to all-female founding teams. In an industry where women and people of color have historically struggled to get a first meeting, let alone a first check, that allocation is itself a kind of thesis statement.

The portfolio reads like a tour of medicine's blind spots. In cancer detection, Arben backed Malcova, which is building an imaging system its team believes could eventually replace mammography for many women, particularly those whose dense breast tissue makes standard screening unreliable. It's not hard to see why that resonated with Ganz personally.

In addiction medicine, the fund backed NorthStar Care, an at-home alcohol use disorder program built on a simple but often overlooked premise: addiction is a biological and metabolic condition, not a failure of willpower. That framing matters. Patients treated as morally deficient tend to disengage from care. Patients treated as having a medical condition tend to stick with treatment.

And in behavioral health infrastructure, Arben invested in Allia Health, an AI-native electronic health record now used by roughly 8,000 providers. Allia's system scans clinical notes for signs of missed diagnoses, flagging things like early psychosis or thyroid issues that a rushed clinician visit might overlook. It's a kind of safety net stitched into the paperwork itself, catching what busy, overworked doctors sometimes can't.

"We're investing in things we think should exist more, rather than trying to judge whether something is good or bad today," Ganz said.

That's a notably humble investment philosophy in an industry often obsessed with picking guaranteed winners. Rather than betting on certainty, Arben is betting on necessity: does the world need more of this, regardless of whether this particular company becomes the market leader?

Ganz is now raising a larger fund. The goal, she said, is to give founders more meaningful capital earlier in their journey, the kind of support that can shorten the painfully long road between an unconventional idea and something patients and providers can actually use. Nine years passed between Ganz's first symptom and her diagnosis. She's trying to make sure the next good idea in medicine doesn't take nearly that long to reach the people who need it.

Why It Matters

Precision medicine promises care tailored to the individual rather than the statistical average, but that promise only becomes real if someone is willing to fund the unproven, unglamorous ideas before they're validated by bigger players. Arben's track record, four FDA clearances and $200 million in follow-on capital from just 83 bets, suggests early conviction capital can meaningfully speed up how fast new diagnostic tools and care models reach patients.

There's a broader lesson here too. Ganz's own medical story, nearly a decade of being told her symptoms fit a familiar pattern when they didn't, is not unusual. Many patients, especially women and people from underrepresented groups, report similar experiences of being dismissed by a system calibrated for the statistical middle. Funding decisions about which startups get capital, and which founders get backed, are quietly shaping whether that pattern continues or finally starts to change.